Explore the vast range of titles available.

\"The Expressionist Figure' documents a collection amassed over more than 60 years and recently gifted to the Walker, which includes some 80 superlative works on paper that focus on the figure. Dating from 1900 to 2018, the drawings span more than a century of artistic experimentation in the US and Europe and were executed in mediums ranging from graphite, ink and crayon to pastel, gouache and collage. Among the artists represented are Milton Avery, Max Beckmann, Christo, Chuck Close, Edgar Degas, Willem de Kooning, Otto Dix, Marlene Dumas, Arshile Gorky, David Hockney, Jasper Johns, William Kentridge, Ernst Ludwig Kirchner, Paul Klee, Gustav Klimt, Renâe Magritte, Henri Matisse, Joan Mirâo, Claes Oldenburg, Pablo Picasso, Sigmar Polke, Egon Schiele, Ben Shahn, Zak Smith and Andy Warhol. Published on the occasion of the first exhibition of this collection, this luxurious volume includes full-page color reproductions of each drawing along with a catalog entry detailing the history of each object. Also included are an essay by the collector on his passion for drawing, and curator Joan Rothfuss' deeply researched short essays on 14 individual works. Both beautiful and substantive, 'The Expressionist Figure' is a testament to the pleasure of building a collection and the rewards of sharing it.\"--Publisher's description.

Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy, who had been disease-free for at least 6 months following last infused cycle of platinum. Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m2 of body surface area] and carboplatin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as maintenance every 3 weeks until disease progression or unacceptable toxicity. Individuals who participated in both the bevacizumab objective and surgical objective (which is ongoing) were randomly assigned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cytoreductive surgery. Randomisation for the bevacizumab objective was stratified by treatment-free interval and participation in the surgical objective. The primary endpoint was overall survival, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00565851. Between Dec 10, 2007, and Aug 26, 2011, 674 women were enrolled and randomly assigned to standard chemotherapy (n=337) or chemotherapy plus bevacizumab (n=377). Median follow-up at the end of the trial on Nov 5, 2014, was 49·6 months in each treatment group (IQR 41·5–62·2 for chemotherapy plus bevacizumab; IQR 40·8–59·3 for chemotherapy), at which point 415 patients had died (214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group). Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevacizumab group was 42·2 months (95% CI 37·7–46·2) versus 37·3 months (32·6–39·7) in the chemotherapy group (hazard ratio [HR] 0·829; 95% CI 0·683–1·005; p=0·056). We identified incorrect treatment-free interval stratification data for 45 (7%) patients (equally balanced between treatment groups); a sensitivity analysis of overall survival based on the audited treatment-free interval stratification data gave an adjusted HR of 0·823 (95% CI 0·680–0·996; p=0·0447). In the safety population (all patients who initiated treatment), 317 (96%) of 325 patients in the chemotherapy plus bevacizumab group had at least one grade 3 or worse adverse event compared with 282 (86%) of 332 in the chemotherapy group; the most frequently reported of these in the chemotherapy plus bevacizumab group compared with the chemotherapy group were hypertension (39 [12%] vs two [1%]), fatigue (27 [8%] vs eight [2%]), and proteinuria (27 [8%] vs none). Two (1%) treatment-related deaths occurred in the chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%) in the chemotherapy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secondary malignancy [n=1]; deaths not classified with CTCAE terms: disease progression [n=3], sudden death [n=1], and not specified [n=1]). The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity analysis based on corrected treatment-free interval stratification indicates that this strategy might be an important addition to the therapeutic armamentarium in these patients. National Cancer Institute and Genentech.

For evacuations, people must make the critical decision to evacuate or stay followed by a multi-dimensional choice composed of concurrent decisions of their departure time, transportation mode, route, destination, and shelter type. These choices have important impacts on transportation response and evacuation outcomes. While extensive research has been conducted on hurricane evacuation behavior, little is known about wildfire evacuation behavior. To address this critical research gap, particularly related to joint choice-making in wildfires, we surveyed individuals impacted by the 2017 December Southern California Wildfires (n = 226) and the 2018 Carr Wildfire (n = 284). Using these data, we contribute to the literature in two key ways. First, we develop two latent class choice models (LCCMs) to evaluate the factors that influence the decision to evacuate or stay/defend. We find an evacuation keen class and an evacuation reluctant class that are influenced differently by mandatory evacuation orders. This nuance is further supported by different membership of people to the classes based on demographics and risk perceptions. Second, we develop two portfolio choice models (PCMs), which jointly model choice dimensions to assess multi-dimensional evacuation choice. We find several similarities between wildfires including a joint preference for within-county and nighttime evacuations and a joint dislike for within-county and highway evacuations. Altogether, this paper provides evidence of heterogeneity in response to mandatory evacuation orders for wildfires, distinct membership of populations to different classes of people for evacuating or staying/defending, and clear correlation among key wildfire evacuation choices that necessitates joint modeling to holistically understanding wildfire evacuation behavior.

Values lie at the heart of an individual’s belief system, serving as prototypes from which attitudes and behaviors are subsequently manufactured. Attitudes and behaviors may evolve over time, but values represent a set of more enduring beliefs. This study examines the influence of values on travel mode choice behavior. It is argued that personal values influence individual attitudes towards different alternative attributes, which in turn impact modal choices. Using data from a sample of 519 German commuters drawn from a consumer panel, the study estimates an integrated choice and latent variable model of travel mode choice that allows for hierarchical relationships between the latent variables and flexible substitution patterns across the modal alternatives. Results from the empirical application support the value-attitude-behavior hierarchical model of cognition, and provide insights to planners and policy-makers on how better to sell public transit as a means of travel.

Automated driving technologies are currently penetrating the market, and the coming fully autonomous cars will have far-reaching, yet largely unknown, implications. A critical unknown is the impact on traveler behavior, which in turn impacts sustainability, the economy, and wellbeing. Most behavioral studies, to date, either focus on safety and human factors (driving simulators; test beds), assume travel behavior implications (microsimulators; network analysis), or ask about hypothetical scenarios that are unfamiliar to the subjects (stated preference studies). Here we present a different approach, which is to use a naturalistic experiment to project people into a world of self-driving cars. We mimic potential life with a privately-owned self-driving vehicle by providing 60 h of free chauffeur service for each participating household for use within a 7-day period. We seek to understand the changes in travel behavior as the subjects adjust their travel and activities during the chauffeur week when, as in a self-driving vehicle, they are explicitly relieved of the driving task. In this first pilot application, our sample consisted of 13 subjects from the San Francisco Bay area, drawn from three cohorts: millennials, families, and retirees. We tracked each subject’s travel for 3 weeks (the chauffeur week, 1 week before and 1 week after) and conducted surveys and interviews. During the chauffeur week, we observed sizable increases in vehicle-miles traveled and number of trips, with a more pronounced increase in trips made in the evening and for longer distances and a substantial proportion of “zero-occupancy” vehicle-miles traveled.

An NCI-sponsored, randomized clinical trial tested whether patients with relapsed ovarian cancer might benefit from surgical debulking of tumors followed by chemotherapy, as compared with chemotherapy alone. No significant outcome differences were noted between the patients who underwent surgery and those treated with chemotherapy alone.

This paper is motivated by the increasing popularity of efficient designs for stated choice experiments. The objective in efficient designs is to create a stated choice experiment that minimizes the standard errors of the estimated parameters. In order to do so, such designs require specifying prior values for the parameters to be estimated. While there is significant literature demonstrating the efficiency improvements (and cost savings) of employing efficient designs, the bulk of the literature tests conditions where the priors used to generate the efficient design are assumed to be accurate. However, there is substantially less literature that compares how different design types perform under varying degree of error of the prior. The literature that does exist assumes small fractions are used (e.g., under 20 unique choice tasks generated), which is in contrast to computer-aided surveys that readily allow for large fractions. Further, the results in the literature are abstract in that there is no reference point (i.e., meaningful units) to provide clear insight on the magnitude of any issue. Our objective is to analyze the robustness of different designs within a typical stated choice experiment context of a trade-off between price and quality. We use as an example transportation mode choice, where the key parameter to estimate is the value of time (VOT). Within this context, we test many designs to examine how robust efficient designs are against a misspecification of the prior parameters. The simple mode choice setting allows for insightful visualizations of the designs themselves and also an interpretable reference point (VOT) for the range in which each design is robust. Not surprisingly, the D-efficient design is most efficient in the region where the true population VOT is near the prior used to generate the design: the prior is $20/h and the efficient range is $10–$30/h. However, the D-efficient design quickly becomes the most inefficient outside of this range (under $5/h and above $40/h), and the estimation significantly degrades above $50/h. The orthogonal and random designs are robust for a much larger range of VOT. The robustness of Bayesian efficient designs varies depending on the variance that the prior assumes. Implementing two-stage designs that first use a small sample to estimate priors are also not robust relative to uninformative designs. Arguably, the random design (which is the easiest to generate) performs as well as any design, and it (as well as any design) will perform even better if data cleaning is done to remove choice tasks where one alternative dominates the other.

The dose-dense delivery of chemotherapy (greater frequency of drug delivery) was explored in women with advanced ovarian cancer. All patients received carboplatin; half received paclitaxel weekly and half every 3 weeks. There were no between-group differences in progression-free survival. Ovarian cancer, the most lethal gynecologic cancer, is responsible for approximately 14,000 deaths in the United States annually. 1 The incorporation of bevacizumab, a monoclonal antibody against vascular endothelial growth factor, in the treatment regimen prolongs progression-free survival but not overall survival. 2 – 5 A dose-dense regimen of paclitaxel involving greater frequency of drug delivery may enhance its antineoplastic effect by eliciting antiangiogenic and proapoptotic properties. 6 – 9 Weekly paclitaxel therapy prolonged survival among patients with early-stage breast cancer and those with metastatic breast cancer. 10 , 11 In a study involving patients with ovarian cancer, Japanese investigators found that dose-dense weekly paclitaxel prolonged progression-free . . .

A decade ago, Hoover‐Dempsey and Sandler offered a model of the parental involvement process that focused on understanding why parents become involved in their children’s education and how their involvement influences student outcomes. Since then, we and others have conducted conceptual and empirical work to enhance understanding of processes examined in the model. In this article (companion to Walker and colleagues’ article about scale development on the model in this issue), we review recent work on constructs central to the model’s initial question: Why do parents become involved in children’s education? Based on this review, we offer suggestions for (1) research that may deepen understanding of parents’ motivations for involvement and (2) school and family practices that may strengthen the incidence and effectiveness of parental involvement across varied school communities.

In a trial of adjuvant chemotherapy for ovarian cancer, a regimen of intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel was superior to intravenous paclitaxel plus intravenous cisplatin. In a trial of adjuvant chemotherapy for ovarian cancer, a regimen of intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel was superior to intravenous paclitaxel plus intravenous cisplatin. Ovarian cancer is the leading cause of death from a gynecologic cancer in the United States. 1 In most cases, the high death rate is due to tumor that has spread beyond the ovary at the time of diagnosis. 2 In the United States, the standard chemotherapy for the initial treatment of ovarian cancer is a combination of a platinum analogue with paclitaxel. 3 , 4 With modern surgical interventions and contemporary chemotherapy, most patients attain complete clinical remission. 3 , 5 The majority of them, however, will eventually have a relapse and die of the disease. The peritoneal cavity is the principal site of disease . . .